BenevolentAI
ben results and progress to date novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in only years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
60 of 74
Similar slides by BenevolentAI
See diffirences between slides (animation)
Results
March 2023
ben results and progress to date target identification chemistry clinical development novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in delivered drug candidate within years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI
Investor Conference
January 2023
ben results and progress to date target identification chemistry clinical development novel target for rapid and lead developing responder and progression | BenevolentAI
Investor Presentation
October 2022
ben results and progress to date novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in only years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI
Investor Presentation
June 2022
ben results and progress to date | BenevolentAI
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io